[Skip to content]

European Parkinson's Disease Association
Search our Site
.

EPNN Journal Issue 05 - Autumn 2005

Next issue
Issues
Previous Issue
EPNN Journal issue 05
Click on image to download

Contents

  • What your patients need to know before a hospital visit


    Susan Calne explains the importance of preparing patients properly for a hospital visit.

  • Wearing off in Parkinson's – how can tolcapone help?

    Tolcapone is the only drug to be withdrawn and then re-instated. Kaye McIntosh reports.

  • Recognising depression in patients with PD


    David Burn summarises some of the key issues concerning depression in PD.

  • Infusing levodopa to stabilise blood levels

    Infusions of levodopa are the only means of ensuring stable plasma concentrations of the drug. Dag Nyholm explains.

  • UK community pharmacy programme makes steady progress
    Geraldine Mynors brings readers up to date with the Community Pharmacist project.
  • How physiotherapy can help at all stages of PD


    Mariella Graziano describes how physiotherapy acts as an adjunct to drug therapy.

  • How to ensure quality care for people with PD


    How does the NSF for Long Term Conditions affect people with PD? Ian Philp discusses aspects of the document with Mary Fogarty.

  • How palliative care works in the UK


    Lucy Sutton describes the work of the National Council for Palliative Care in England, Wales and Northern Ireland.

  • Early start with ropinirole


    Patients with PD who begin their treatment early after diagnosis with ropinirole only do better than those who commence with levodopa only.

  • Phoenix Days


    People with PD who have young children now have the opportunity to mix with other families in a similar situation by going on a ‘Phoenix Days’ holiday.

  • Good evidence and a licence for rasagiline

    Data presented at the 9th International Congress on Parkinson’s disease in Berlin showed that early treatment with the MAO-B inhibitor rasagiline has a positive effect on the functional impairments associated with Parkinson’s disease and that the effects of the drug are maintained for up to 6.5 years.

  • Ibuprofen associated with lower risk of PD


    A study in the US of almost 150,000 people has suggested that the use of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen is associated with a lower risk of Parkinson’s disease.

  • Pergolide can affect aortic valve

    Pergolide appears to be associated with an increased risk of developing a problem with the aortic valve, the main outlet of the heart, according to a study conducted at the Mayo Clinic College of Medicine in Jacksonville.

  • Ovary removal leads to greater risk of PD


    Surgical removal of both ovaries can almost double a woman’s risk of developing PD or parkinsonism later on in life.